Table 1.
Demographic and Clinical Characteristics of the Study Population at Baseline
| Clinical Values | All Patients (N = 80) |
|---|---|
| Age, y | 73.5 ± 11.8 |
| Sex | |
| Male | 34 (42.5%) |
| Female | 46 (57.5%) |
| Race | |
| White | 50 (62.5%) |
| Black | 27 (33.8%) |
| Asian | 3 (3.7%) |
| Remission status | |
| Achieved and maintained P/C remission | 32 (40.0%) |
| Achieved P/C remission and relapsed | 26 (32.5%) |
| Never achieved P/C remission | 22 (27.5%) |
| Therapies1 | |
| Prednisone | 68 (85.0%) |
| Rituximab | 23 (28.8%) |
| Mycophenolate mofetil | 24 (30.0%) |
| Methotrexate | 9 (11.3%) |
| Dapsone | 9 (11.3%) |
| Azathioprine | 10 (12.5%) |
| Doxycycline | 16 (20.0%) |
| IVIg | 3 (3.8%) |
| Sulfasalazine | 3 (3.8%) |
| Other immune modulating therapy | 12 (15.0%) |
| BPDAI TAS | 16.8 (6.9–36.6) |
| BPDAI PCS | 20.0 (9.0–26.0) |
| BP180, U/ml | 41.0 (0–115.0) |
| BP230, U/ml | 0 (0–38.0) |
| Duration of follow-up, mo | 15.05 (6.0–34.5) |
Abbreviations: BPDAI, Bullous Pemphigoid Disease Area Index; PCS, pruritus component score; P/C, partial/complete; Q, quartile; TAS, total activity score.
Data are presented as mean ± SD for normally distributed variables, median (Q1, Q3) for asymmetrically distributed variables, or count (percentage) for categorical variables. BPDAI scores were calculated according to Murrell et al. (2012).
1
Sums to greater than 100% owing to patients on dual therapy.